A strain of Enterococcusfaecalis (A256) was isolated from the urine of a patient with urinary sepsis and was found to exhibit susceptibilities (micrograms per milliliter) to various glycopeptides as follows: vancomycin, 256; teicoplanin, 16; 62208, 512; 62211, 4; and 62476, 16. As judged by growth rates before and after exposure to sub-MICs of glycopeptides, vancomycin and 62476 induced self-resistance, 62208 and 62211 induced slight self-resistance, and teicoplanin did not induce self-resistance. Vancomycin induced cross-resistance to all other glycopeptides tested, as judged both in growth experiments and by direct measurement of inhibition of peptidoglycan synthesis in cells exposed to sub-MICs of vancomycin. Thus, the spectra of activity of the glycopeptides were not correlated with their patterns of induction. There was a correlation between the increased synthesis of a 39-kilodalton (kDa) protein located in the cytoplasmic membrane and the induction of resistance. Protoplasts of A256 were susceptible to inhibition of peptidoglycan synthesis by vancomycin at levels similar to those for susceptible strains. Vancomycin resistance was transferable on filters from the parent strain to E. faecalis JH2-2 at a frequency of about 10-7, and the 39-kDa protein was also inducible by glycopeptides in these transconjugants. We conclude that A256 is resistant to glycopeptides by virtue of the synthesis of a 39-kDa cytoplasmic membrane protein, that this protein is probably involved in preventing access of the glycopeptides to their peptidoglycan targets, and that this resistance is transferable, probably by conjugation.
A strain of Enterococcusfaecalis (A256) was isolated from the urine of a patient with urinary sepsis and was found to exhibit susceptibilities (micrograms per milliliter) to various glycopeptides as follows: vancomycin, 256; teicoplanin, 16; 62208, 512; 62211, 4; and 62476, 16 . As judged by growth rates before and after exposure to sub-MICs of glycopeptides, vancomycin and 62476 induced self-resistance, 62208 and 62211 induced slight self-resistance, and teicoplanin did not induce self-resistance. Vancomycin induced cross-resistance to all other glycopeptides tested, as judged both in growth experiments and by direct measurement of inhibition of peptidoglycan synthesis in cells exposed to sub-MICs of vancomycin. Thus, the spectra of activity of the glycopeptides were not correlated with their patterns of induction. There was a correlation between the increased synthesis of a 39-kilodalton (kDa) protein located in the cytoplasmic membrane and the induction of resistance. Protoplasts of A256 were susceptible to inhibition of peptidoglycan synthesis by vancomycin at levels similar to those for susceptible strains. Vancomycin resistance was transferable on filters from the parent strain to E. faecalis JH2-2 at a frequency of about 10-7, and the 39-kDa protein was also inducible by glycopeptides in these transconjugants. We conclude that A256 is resistant to glycopeptides by virtue of the synthesis of a 39-kDa cytoplasmic membrane protein, that this protein is probably involved in preventing access of the glycopeptides to their peptidoglycan targets, and that this resistance is transferable, probably by conjugation.
Enterococcus faecalis and E. faecium are common causes of infection in humans (6, 19) . These infections can be difficult to treat because of the degree of antibiotic resistance normally conferred to these strains by chromosomal or plasmid-borne determinants (12, 16 ). This appears to be especially true for E. faecium, which tends to be more resistant to aminoglycoside-beta-lactam synergy than E. faecalis (16) . For strains with high levels of beta-lactam resistance or when beta-lactams are poorly tolerated by the patient, glycopeptide antibiotics, mainly vancomycin, have been used in treatment with favorable results. A new glycopeptide, teicoplanin, is in clinical trials in the United States and Europe (14) . Recently, reports of glycopeptide-resistant enterococcal strains have appeared in the literature (11, 13, 22) . Two such strains of E. faecium with transferable, plasmid-mediated, glycopeptide resistance have been described (13) . In the latter study, for Streptococcuis sanquis strains carrying the plasmids but not for the enterococcal parent strains, glycopeptide MICs were shown to be increased after preexposure to low concentrations of glycopeptides, suggesting inducible resistance. We here present data regarding the mechanism of resistance in a glycopeptide-resistant strain of E. faecalis, A256.
MATERIALS AND METHODS
Bacterial strains. A256 is an E. faecalis strain isolated from the urine of a patient with recurrent urinary tract infection and urosepsis at Hotel Dieu in Paris, France, early in 1988. A review of records revealed that the patient had not been treated with glycopeptides during the 3 years preceding the onset of this infection. A256 was identified as E. faecalis by conventional methods (6) , API 20 STREP System (API System S.A., La Balme les Grottes, France), and penicillinbinding protein profile (23) . D15 is a glycopeptide-susceptible strain of E. faecalis, and strain JH2-2 was used as a recipient in genetic crosses (9) . Strains with DSV numbers represent vancomycin-resistant transconjugants resulting from matings between A256 and JH2-2.
Susceptibility testing. MICs were determined by plating 1,000 bacteria per spot on brain heart infusion (BHI) agar containing antibiotics diluted serially. Plates were incubated overnight at 37°C.
Antibiotics. Glycopeptides used were vancomycin (Eli Lilly, & Co., Indianapolis, Ind.); and teicoplanin, 62208, 62476, and 62211 (Lepetit Research Center, Milan, Italy). 62476 has been reported by Goldstein et al. (8) as A40926 component B. It has only one chloride, compared to two for vancomycin and teicoplanin, and two sugar substituents, compared to one for vancomycin and two to three for the teicoplanin complex. 62208 and 62211 are both N-acylated derivatives of teicoplanin, and both carry two chlorides (personal communication from B. Goldstein and F. Parenti of the Lepetit Research Center). 62208 is the aglycone, whereas 62211 has three sugar substituents. Penicillin was benzylpenicillin G.
Measurement of peptidoglycan synthesis. Strains were grown overnight in M3 or BHI broth, diluted 1:100, to late log phase. Cells were harvested by centrifugation at 5,900 x g at 4°C and washed twice in distilled water. Cells were suspended in 0.2 x wall-thickening medium (1, 20) plus 50 ,ug of chloramphenicol per ml (the MIC of chloramphenicol for all strains was <32 ,ug/ml) and 0.5 p.Ci of [3H]N-acetylglucosamine per ml and incubated at 37°C for 1 h in the presence of various concentrations of glycopeptides. Under these conditions, only cell wall material is produced (1, 20) . Cells were then centrifuged, and the pellets were treated as described below. Radioactivity was determined by precipitating the peptidoglycan of whole cells in cold 5% (wt/vol) trichloroacetic acid, filtering with glass fiber filters (Whatman GFA), and washing the filters with cold 10% (wt/vol) trichloroacetic acid, followed by 95% (vol/vol) ethanol, drying, and counting in a liquid scintillation counter.
Preparation of protoplasts. Strain A256 was grown in M3 broth and concentrated as described above, except that cells were washed in 20% sucrose. Protoplasts were prepared as previously described (10) , except that 10 ,l each of lysozyme (10 mg/ml) and Ml-muramidase (2.5 mg/ml) was added to the cell pellet to form protoplasts. Protoplasting was confirmed microscopically. The protoplasts were then used to measure inhibition of peptidoglycan synthesis by vancomycin by using wall-thickening medium supplemented with 20% sucrose.
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis.
For analysis of total cell proteins, cells in logarithmic growth (optical density at 650 nm [OD650], 0.2) were harvested and lysed by using Ml-muramidase plus lysozyme. To separate cell components, 200 ml of log-phase cells was centrifuged and washed twice in an equal volume of 0.05 M phosphate buffer, pH 7.5. After the cells were broken by agitation in the presence of glass beads, cell walls were collected by centrifugation at 5,900 x g, and membranes were separated from the resulting supernatant by centrifugation at 100,000 x g for 45 min. The final supernatant was considered to represent, mainly, cytoplasmic proteins. Extracts were layered on 10% polyacrylamide gels containing sodium dodecyl sulfate with a 5% stacking gel and electrophoresed at 100 V for 1 h and 150 V for 4 h, or until the tracking dye was just above the bottom of the gel. Protein bands were stained with Coomassie blue. Transfer of vancomycin resistance. Strain A256 was mixed with strain JH2-2 on filters as previously described (12) , and transconjugants were selected on BHI agar containing 100 ,ug of rifampin, 32 ,ug of fusidic acid, and 64 ,ug of vancomycin per ml. Total DNA was extracted by first lysing 1.4 ml of an overnight culture with lysozyme plus Ml-muramidase and then extracting total DNA by using the method of Ish and Horowicz (15) , except that no alkaline precipitation of chromosomal DNA was done. The extracts were then run in 0.7% agarose gels, and plasmid bands were visualized with UV transillumination after ethidium bromide staining.
RESULTS
A256 is resistant to glycopeptides. The MICs of various glycopeptides for strain A256, susceptible control strains of E. faecalis (D15 and JH2-2), and a transconjugant, DSV-1, derived from the mating between A256 and JH2-2, are shown in Table 1 . There was no effect of increasing the inoculum from 103 to 106 CFU per spot (data not shown). The MICs of all glycopeptides were increased for A256. The MICs were not affected by pregrowth in the presence of vancomycin (data not shown).
By comparing detailed structures of the compounds studied, no specific structure-activity relationships were apparent. However, there was a rough correlation with the number of sugar substituents and activity. 62211 was the most active glycopeptide with three sugars; teicoplanin and 62476 were moderately active with two; and vancomycin, with a disaccharide substituent at a single site, and 62208, the aglycone, were the least active.
Glycopeptide resistance in A256 is inducible. Since E. faecalis is usually not killed by glycopeptides (this was true for strain A256), if glycopeptide resistance were inducible, one would not expect the MICs of the glycopeptides for A256 to change after preexposure to the antibiotics. That is, the nonkilled cells would remain viable but nongrowing in antibiotic-containing medium until resistance had been induced and would then grow. This, in fact, was the case. Therefore, to test for inducible resistance, dynamic-growth experiments were required. For these experiments, strains were grown overnight in BHI without or with subinhibitory (1/4x MIC) concentrations of each glycopeptide. Each was diluted in medium identical to that which had been used for overnight growth. When log growth was achieved (OD650, 0.2), each was then rediluted to an OD650 of about 0.02. However, cells grown previously without antibiotic were then diluted in antibiotic-containing medium and also in control medium without antibiotic. The resulting growth curves are shown in Fig. 1 . The generation times derived from these growth curves are shown in Table 2 . Pregrowth in the presence of any of the glycopeptides, except teicoplanin, appeared to shorten the generation times for subsequent growth of A256 in the presence of the pregrowth compound. Thus, teicoplanin appeared not to induce self-resistance as well as did the other agents. Pregrowth in sub-MICs of vancomycin did not improve subsequent growth in the presence of vancomycin for D15, our susceptible control strain (results not shown).
If resistance to glycopeptides seems to be inducible, it is possible that only a small number of cells in the population express resistance and that they are then selected in the presence of antibiotic or that induction occurs in all the cells in the population. Thus, we compared viable counts of strain A256 from cultures that had been pregrown in the presence or absence of vancomycin plated on BHI agar containing no antibiotic or 64 pjg of vancomycin per ml. We observed no difference in viable counts when cultures at an OD650 of 0.2 pregrown in the presence and absence of vancomycin were plated in the presence and absence of vancomycin. This is consistent with the hypothesis that the resistance is expressed in most cells in the population after induction.
Vancomycin induces resistance to other glycopeptides. Strain A256 was grown overnight in the presence or absence of 64 ,ug of vancomycin per ml (1/4x MIC). These cells were then diluted under similar conditions in the morning and grown to an OD650 of 0.2 and then rediluted as indicated above in medium containing 1/4x MICs of the glycopeptides. The generation times derived from this experiment are shown in Table 3 . It appeared that pregrowth in vancomycin shortened the generation times for subsequent growth with each of the other four glycopeptides.
We also measured the induction of resistance to inhibition of peptidoglycan synthesis by various glycopeptides after pregrowth in the presence of vancomycin. Strain A256 was grown overnight in 64 ,ug of vancomycin per ml in BHI and also in BHI without antibiotic. These cultures were diluted in the morning in similar media. When cultures reached an OD650 of 0.2, they were collected, washed, and incubated in wall-thickening medium plus 0.5 ,uCi of [3H]N-acetylglucosamine per ml, as described in Materials and Methods. Various concentrations of glycopeptides were then added to these cultures, and the percent inhibition of uptake of labeled wall precursor was measured. The results are shown in Table 4 . The data confirmed the induction of resistance to other glycopeptides by pregrowth of A256 in the presence of vancomycin. Similar experiments performed with the glycopeptide-susceptible strain, D15, revealed no induction of resistance ( Table 4) .
Induction of resistance is correlated with the synthesis of a 39-kDa cytoplasmic membrane protein. The results of sodium dodecyl sulfate-10% polyacrylamide gel electrophoresis of total cell proteins of strain A256 before and after exposure to sub-MICs of vancomycin are shown in Fig. 2 . A protein of 39 kilodaltons (kDa) appeared after exposure of cells to vancomycin, and this protein was not visible in the strain before antibiotic exposure. This protein appeared between 30 and 45 min of exposure to vancomycin (results not shown). This protein also appeared after exposure to each of the four other glycopeptides tested (results not shown). No protein of similar molecular size was detected after exposure of several glycopeptide-susceptible strains of E. faecalis, including JH2-2 and D15, to 1/4 to 1/2x MICs of vancomycin (results not shown). Furthermore, no such protein was observed after exposure of A256 to sub-MICs of penicillin, rifampin, or fusidic acid (results not shown). Therefore, we believe that the appearance of the 39-kDa protein is a specific response of A256 to glycopeptides.
We also demonstrated by cell fractionation techniques that this protein was found mainly in the fraction enriched for cytoplasmic membranes. By our fractionation method (see Materials and Methods), contamination of the cell wall fraction with cytoplasmic membranes is expected. However, by microscopic examination, the cytoplasmic membrane fraction was not contaminated by cell walls or whole cells. Therefore, the fact that we found the protein in both the wall fraction and the membrane fraction indicated that it was a membrane-associated protein.
Protoplasts of A256 become susceptible to inhibition of peptidoglycan synthesis by vancomycin. Pregrowth in the presence of vancomycin resulted in much higher levels of resistance to inhibition of peptidoglycan synthesis by glyco- (Table 4 ). It also appeared that, even in the uninduced state, A256 was more resistant to vancomycin than D15, a susceptible control strain ( Fig. 3 and Table 4 ). For example, A256 uninduced showed 47 to 61% inhibition of peptidoglycan synthesis at 32 ,ug of vancomycin per ml compared with 87 and 87% inhibition for D15 at the same concentration of vancomycin in two experiments. Protoplasts of uninduced A256, however, were just as susceptible as our glycopeptide-susceptible control strain, D15, and were more susceptible than intact (uninduced) A256 cells (Fig. 3) . These data suggested that the 39-kDa membrane protein must interact with the cell wall for resistance to occur.
Inducible resistance is transferable on filters to E. faecalis JH2-2. Strain A256 was used as a donor and JH2-2 was used as a recipient in filter matings. Vancomycin resistance was transferred at a frequency of about io-7. The donor contained four plasmid DNA bands which were transferred, in various combinations, to only 3 of 20 transconjugants tested. It is possible, therefore, that inducible vancomycin resistance in A256 is chromosomally determined. However, a conjugative transposon, perhaps encoded on an unstable plasmid, remains a viable alternative. The induction of the 39-kDa protein by growth of one of the transconjugants in sub-MICs of vancomycin is also shown in Fig. 2 .
DISCUSSION
Because of worldwide endemic levels of staphylococci resistant to methicillin, the existence of penicillin allergy among patients with serious infections caused by grampositive organisms, and the improved purity of vancomycin with its relative lack of toxicity (7) , the latter compound has enjoyed increased use worldwide. Recent reports have noted the emergence of opportunistic gram-positive pathogens, such as Leuconostoc and Lactobacillus spp., which are naturally resistant to glycopeptides (3, 5) . Also, glycopeptide-resistant Staphylococcus haemolyticus has been recently reported as a human pathogen (18; R. S. Schwalbe, Alliance Prudent Use Antibiot. Newsl. 5:1-2, 1987). Within the past year, an outbreak of glycopeptide-resistant enterococcal strains was reported (23); and a publication describing another strain, isolated from a patient receiving vancomycin prophylaxis, recently appeared (11) . VOL. 33, 1989 ANTIMICROB. AGENTS CHEMOTHER.
FIG. 2. Sodium dodecyl sulfate-10% polyacrylamide gel electrophoresis of whole-cell lysates of strain A256 and a JH2-2 transconjugant. Lanes: 1, A256 without pregrowth in the presence of 64 ,ug of vancomycin per ml; 2, A256 after pregrowth in the presence of 64 ,ug of vancomycin per ml; 3, DSV-7 (a vancomycin-resistant JH2-2 transconjugant) after pregrowth in the presence of 64 ,ug of vancomycin per ml; 4, DSV-7 without pregrowth with vancomycin; 5, JH2-2; 6, molecular size markers as indicated. The protein of 39 kDa is indicated by arrowheads in appropriate lanes.
Leclercq and co-workers recently reported plasmid-mediated resistance to glycopeptides in two strains of E. faecium (13) . In their work, it appeared that the glycopeptide susceptibilities of S. sanguis transformants decreased after preexposure to low concentrations of glycopeptides, suggesting induction of resistance. Leclercq et al. did not demonstrate any change in MICs of glycopeptides for the enterococcal parents after preexposure to vancomycin. Our strain appears to have a resistance phenotype similar to that of the strains they studied. We observed no change in MIC after preexposure to sub-MICs either for the parent strain or for JH2-2 transconjugants, but inducible resistance could be demonstrated by other means. This suggested that induction occurs during growth on antibiotic-containing medium. Since E. faecalis is not killed by vancomycin, induction may be allowed to occur after plating, whereas it might not occur in S. sanguis under these conditions because of the rapidly lethal effect of vancomycin for S. sanguis.
Although structure-activity relationships among the glycopeptides against strain A256 were not obvious, there did seem to be a correlation with the number of sugar substituents. In other work (D. M. Shlaes, S. Al-Obeid, J. H. Shlaes, and R. Williamson, J. Infect. Dis., in press) with a strain of E. faecium (D366) with another mechanism of vancomycin resistance, we were able to show a correlation with hydrophobicity of glycopeptides and activity, an observation consistent with the membrane location of the induced protein in both A256 and D366. E. faecalis A256 is more resistant to vancomycin and 62208 than to teicoplanin, 62211, and 62476; yet induction of resistance by vancomycin and 62476 is stronger than that by teicoplanin, 62208, and 62211. No structure-induction potential relationships were apparent. This suggests the possibility that the receptor for induction might be different from the antibiotic target, which is presumed to be the terminal D-alanyl-D-alanine of the growing peptidoglycan chain (17) .
That induction of resistance appears to correlate with induction of a 39-kDa inner-membrane protein is suggested by the increase in density of this band in whole-cell lysates and in membranes of strain A256 and of vancomycinresistant JH2-2 transconjugants after exposure to vancomycin. This protein is not induced during exposure of glycopeptide-susceptible strains to vancomycin or by exposure of glycopeptide-resistant strains to other antibiotics, including cell-wall-active agents such as penicillin. We previously observed inducible vancomycin resistance in a strain of E. faecium, D366 (R. Williamson, S. Al-Obeid, J. H. Shlaes, F. W. Goldstein, and D. M. Shlaes, J. Infect. Dis., in press). D366 also demonstrates glycopeptide-induced synthesis of a membrane protein differing in size slightly from that induced in A256.
The exact role of the 39-kDa protein that appears in strain A256 after exposure to glycopeptides also remains unclear. We assayed for antibiotic destruction by using uninduced and induced A256 and D15, washing, and reexposing to sub-MICs of glycopeptides. We then assayed for loss of activity or antibiotic from supernatants during 90 min of incubation. There was no difference in antibiotic levels in supernatants from induced or uninduced A256 or D15, suggesting that the 39-kDa protein does not destroy the antibiotic (S. Al-Obeid, D. M. Shlaes, J. H. Shlaes, and R. Williamson, unpublished observations). The most likely mechanism of action of the 39-kDa cytoplasmic membrane protein appears to be prevention of glycopeptide access to its peptidoglycan target at the membrane level. The membrane protein in D366 might also be important in protecting the growing peptidoglycan chain from antibiotic access (Williamson et al., in press ). The experiment with A256 protoplasts is consistent with this hypothesis and suggests that interaction of the protein with the cell wall is required for this protection. However, a bypass mechanism or even structural remodeling of the peptidoglycan to eliminate the possibility of interaction of glycopeptides with the D-alanyl-D-alanine targets cannot be ruled out. Clearly, further characterization of the 39-kDa protein is required before the exact mechanism of glycopeptide resistance in these strains can be understood. The mechanism of resistance in other glycopeptide-resistant enterococcal strains remains unknown as well.
The presence of a transferable, inducible system of resis-202 SHLAES ET AL.
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203 tance is somewhat reminiscent of the mechanism of methicillin resistance in staphylococci (2, 4, 21) . In this case, the resistance is the result of induction of synthesis of PBP 2a, which is a new cytoplasmic membrane protein target for beta-lactam antibiotics. PBP 2a is apparently encoded by a defective, large transposable element not found in susceptible strains (2) . In E. faecalis A256, resistance to vancomycin is associated with inducible synthesis of a 39-kDa cytoplasmic membrane protein which is transferable in the apparent absence of transfer of plasmid DNA. Whether this resistance is also encoded by a defective transposon or not is a matter of speculation. However, since it has not been possible to select vancomycin-resistant mutants of susceptible enterococcal strains, even by broth enrichment techniques (R. Williamson, unpublished observations), it seems probable that the gene encoding the 39-kDa protein does not exist in susceptible strains. Finally, one might speculate that the fact that vancomycin resistance is transferable might help explain the recently reported outbreak of glycopeptide-resistant enterococci (13, 22) . The evolution of transferable glycopeptide resistance in enterococci emphasizes the need for additional therapeutic alternatives for treatment of serious enterococcal infections.
